SCHEMBL3977084

SCHEMBL3977084

CCOC(=O)c1occc1-c1cccc(Oc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
HTT P42858 3/20 0.52
LMNA P02545 2/20 0.52
ALOX12 P18054 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
PTGS2 P35354 3/20 0.50
SMN1; SMN2 Q16637 5/20 0.48
MAPT P10636 5/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
HPGD P15428 4/20 0.43
KDM4E B2RXH2 3/20 0.43
HSD17B10 Q99714 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
GPR55 Q9Y2T6 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
P2RX3 P56373 1/20 0.43
CYP1A2 P05177 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982536 0.86 TSHR (0.47) ALDH1A1LMNANPSR1SMN1; SMN2MAPT
SCHEMBL3979355 0.84 MAPT (0.45) ALDH1A1HTTLMNANPSR1SMN1; SMN2
SCHEMBL3978291 0.83 HPGD (0.39) ALDH1A1HTTLMNAALOX12NPSR1
SCHEMBL27605323 0.83 MEN1 (0.52) SMN1; SMN2MAPTMEN1KMT2ARAB9A
SCHEMBL3974986 0.83 PTGER4 (0.44) L3MBTL1TDP1POLBFFAR1
SCHEMBL3978230 0.82 PTGS2 (0.40) ALDH1A1HTTLMNAALOX12NPSR1
SCHEMBL3977097 0.82 FNTA (0.46) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL3976847 0.81 SMN1; SMN2 (0.53) ALDH1A1LMNASMN1; SMN2MAPTMEN1
SCHEMBL3981898 0.80 PTGER4 (0.42) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3978096 0.80 MEN1 (0.50) ALDH1A1HTTLMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100543022-C 2-furancarboxylic acid hydrazide compound and contain the pharmaceutical composition of this compound DAINIPPON PHARMACEUTICAL CO (JP) 2009-09-23 CN disclosed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
CN-1628111-A 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO (JP) 2005-06-15 CN disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 ALDH1A1 1389/4885HTT 1770/4885LMNA 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.